Literature DB >> 18719067

Use of prescription and nonprescription medications and supplements by cancer patients during chemotherapy: questionnaire validation.

Marie H Hanigan1, Brian L Dela Cruz, David M Thompson, Kevin C Farmer, Patrick J Medina.   

Abstract

BACKGROUND: Cancer patients take medications for coexisting disease and self-medicate with over-the-counter drugs (OTCs). A complete analysis of the use of prescription drugs, OTCs, and supplements during cancer treatment has never been done.
METHODS: The study developed and validated a self-administered questionnaire on the use of concomitant medications by patients undergoing treatment with chemotherapy. The questionnaire listed 510 prescription medications, OTCs, and supplements (including vitamins, minerals, and herbs). Fifty-two subjects completed the questionnaire while visiting the infusion clinic to receive chemotherapy. On a subsequent visit the subjects brought their medications to the clinic and a pharmacist reviewed their completed questionnaire.
RESULTS: Ninety-six percent of the subjects reported taking prescription medications within 3 days prior to chemotherapy, 71% reported taking OTCs and 69% reported use of supplements. The subjects took an average of 5.5 (range 0-13) prescription drugs, 2.2 (0-20) OTCs, and 1.9 (0-11) supplements. Twenty-one drugs were each taken by at least 10% of the subjects. Acetaminophen was taken by 59.6% of the subjects. One subject reported taking five acetaminophen-containing drugs. The questionnaire's sensitivity was 92.0%, specificity 99.9%.
CONCLUSION: Within 3 days prior to chemotherapy, subjects took an average of 9.6 concomitant medications, many of which alter drug metabolism and or disposition. In clinical trials, multivariate analysis of all concomitant medications could add to clinically relevant data to identify drug interactions that negate or potentiate the efficacy of cancer treatment regimens. In some instances, apparent resistance of tumors to chemotherapy may be the result of drug interactions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18719067      PMCID: PMC2656681          DOI: 10.1177/1078155208090624

Source DB:  PubMed          Journal:  J Oncol Pharm Pract        ISSN: 1078-1552            Impact factor:   1.809


  24 in total

1.  Influence of question structure on the recall of self-reported drug use.

Authors:  O H Klungel; A de Boer; A H Paes; R M Herings; J C Seidell; A Bakker
Journal:  J Clin Epidemiol       Date:  2000-03-01       Impact factor: 6.437

2.  Self-administered questionnaire compared with a personal diary for assessment of current use of hormone therapy: an analysis of 16,060 women.

Authors:  J Merlo; G Berglund; E Wirfält; B Gullberg; B Hedblad; J Manjer; B Hovelius; L Janzon; B S Hanson; P O Ostergren
Journal:  Am J Epidemiol       Date:  2000-10-15       Impact factor: 4.897

3.  Use of complementary health practices by prostate carcinoma patients undergoing radiation therapy.

Authors:  G D Kao; P Devine
Journal:  Cancer       Date:  2000-02-01       Impact factor: 6.860

Review 4.  Antioxidants in cancer therapy; their actions and interactions with oncologic therapies.

Authors:  D W Lamson; M S Brignall
Journal:  Altern Med Rev       Date:  1999-10

5.  Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology.

Authors:  M A Richardson; T Sanders; J L Palmer; A Greisinger; S E Singletary
Journal:  J Clin Oncol       Date:  2000-07       Impact factor: 44.544

6.  Advising patients who seek complementary and alternative medical therapies for cancer.

Authors:  Wendy A Weiger; Michael Smith; Heather Boon; Mary Ann Richardson; Ted J Kaptchuk; David M Eisenberg
Journal:  Ann Intern Med       Date:  2002-12-03       Impact factor: 25.391

7.  Cytochrome P450 expression-induction profile and chemically mediated alterations of the WIF-B9 cell line.

Authors:  Christine Biagini; Virginie Bender; Françoise Borde; Elodie Boissel; Marie-Claire Bonnet; Marie-Thérèse Masson; Doris Cassio; Stephan Chevalier
Journal:  Biol Cell       Date:  2006-01       Impact factor: 4.458

8.  Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study.

Authors:  Anne M Larson; Julie Polson; Robert J Fontana; Timothy J Davern; Ezmina Lalani; Linda S Hynan; Joan S Reisch; Frank V Schiødt; George Ostapowicz; A Obaid Shakil; William M Lee
Journal:  Hepatology       Date:  2005-12       Impact factor: 17.425

9.  Sensitivity and specificity of self-reported use of dietary supplements.

Authors:  M Messerer; A Wolk
Journal:  Eur J Clin Nutr       Date:  2004-12       Impact factor: 4.016

10.  Potential drug interactions and duplicate prescriptions among cancer patients.

Authors:  Rachel P Riechelmann; Ian F Tannock; Lisa Wang; Everardo D Saad; Nathan A Taback; Monika K Krzyzanowska
Journal:  J Natl Cancer Inst       Date:  2007-04-18       Impact factor: 13.506

View more
  14 in total

Review 1.  Polypharmacy and potentially inappropriate medication use in geriatric oncology.

Authors:  Manvi Sharma; Kah Poh Loh; Ginah Nightingale; Supriya G Mohile; Holly M Holmes
Journal:  J Geriatr Oncol       Date:  2016-08-03       Impact factor: 3.599

2.  Adherence to Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma.

Authors:  Hira Mian; Mark Fiala; Tanya M Wildes
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-10-09

Review 3.  Polypharmacy in the Geriatric Oncology Population.

Authors:  Lauren R Hersh; Kathryn Beldowski; Emily R Hajjar
Journal:  Curr Oncol Rep       Date:  2017-09-23       Impact factor: 5.075

4.  Potential medication problems in older newly diagnosed cancer patients in Canada during cancer treatment: a prospective pilot cohort study.

Authors:  Martine T E Puts; Johanne Monette; Veronique Girre; Beatriz Costa-Lima; Christina Wolfson; Gerald Batist; Howard Bergman
Journal:  Drugs Aging       Date:  2010-07-01       Impact factor: 3.923

5.  A pilot study of website information regarding aromatase inhibitors: dietary supplement interactions.

Authors:  Cara L McDermott; Angela A Hsieh; Erin S Sweet; Kimberly M Tippens; Jeannine S McCune
Journal:  J Altern Complement Med       Date:  2011-11       Impact factor: 2.579

6.  Polypharmacy in Patients with Ovarian Cancer.

Authors:  Sean Oldak; Stephanie Ioannou; Priyanka Kamath; Marilyn Huang; Sophia George; Brian Slomovitz; Matthew Schlumbrecht
Journal:  Oncologist       Date:  2019-04-05

7.  Medication problems in older, newly diagnosed cancer patients in Canada: How common are they? A prospective pilot study.

Authors:  Martine T E Puts; Beatriz Costa-Lima; Johanne Monette; Veronique Girre; Christina Wolfson; Gerald Batist; Howard Bergman
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

8.  Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy.

Authors:  Mihaela A Popa; Kristie J Wallace; Antonella Brunello; Martine Extermann; Lodovico Balducci
Journal:  J Geriatr Oncol       Date:  2014-05-10       Impact factor: 3.599

9.  Optimizing chemotherapy: concomitant medication lists.

Authors:  M H Hanigan; B L Dela Cruz; S S Shord; P J Medina; J Fazili; D M Thompson
Journal:  Clin Pharmacol Ther       Date:  2010-12-01       Impact factor: 6.875

10.  Prevalence and effects of polypharmacy on overall survival in acute myeloid leukemia.

Authors:  Prajwal Dhakal; Elizabeth Lyden; Kate-Lynn E Muir; Zaid S Al-Kadhimi; Thuy Koll; Lori J Maness; Krishna Gundabolu; Vijaya Raj Bhatt
Journal:  Leuk Lymphoma       Date:  2020-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.